Publications: Our research

Risk of COVID-19 after natural infection or vaccination

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination

The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century

Safety, immunogenicity, and efficacy of the NVX-CoV2373 Covid-19 vaccine in adolescents a randomized clinical trial

Immunogenicity and safety of NVX-CoV2373 as a Homologous or Heterologous booster: A phase 3 randomized clinical trial in adults

NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial